Navidea Biopharmaceuticals is a US-based company founded in 1983, focused on precision medicine and immuno-targeted products for identifying disease pathways. Using its Manocept™ technology, the company aims to develop targeted diagnostics and therapies for cancer, autoimmune conditions, and inflammatory diseases, primarily focusing on personalized Rheumatoid Arthritis diagnostics. With its headquarters in Dublin, Ohio, the company received a $2.75M Post-IPO Equity investment on 27 April 2023. As a leader in the Biopharma, Biotechnology, and Health Care industries, Navidea Biopharmaceuticals continues to make strides in precision medicine, clinical decision-making, and targeted treatment for improved patient care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $2.75M | - | 27 Apr 2023 | |
| Post-IPO Debt | $1.00M | 1 | John K. Scott | 05 Jul 2022 |
| Post-IPO Debt | $2.50M | - | 12 Apr 2022 | |
| Post-IPO Equity | $5.00M | 1 | John K. Scott | 02 Mar 2021 |
| Post-IPO Debt | $60.00M | 1 |
|
11 May 2015 |
No recent news or press coverage available for Navidea Biopharmaceuticals .
We care about your data, and we'd love to use cookies make your experience better.
